Hormone Sensitive Prostate Cancer Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting hormone sensitive prostate cancer clinical trials across 28 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Nashville, Tennessee, United States, New York, New York, United States, Kaohsiung City, Taiwan. Updated daily from ClinicalTrials.gov.


Hormone Sensitive Prostate Cancer Trials at a Glance

13 actively recruiting trials for hormone sensitive prostate cancer are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Nashville, New York, and Kaohsiung City. Lead sponsors running hormone sensitive prostate cancer studies include Astellas Pharma Global Development, Inc., Bayer, and AdvanCell Pty Limited.

Browse hormone sensitive prostate cancer trials by phase

Treatments under study

About Hormone Sensitive Prostate Cancer Clinical Trials

Looking for clinical trials for Hormone Sensitive Prostate Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hormone Sensitive Prostate Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hormone Sensitive Prostate Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled332 locationsNCT07028853
Recruiting
Phase 2

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer
Novartis Pharmaceuticals150 enrolled67 locationsNCT06991556
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Metastatic Hormone Sensitive Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer600 enrolled1 locationNCT06334120
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.218 enrolled33 locationsNCT07005154
Recruiting

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Bayer1,400 enrolled1 locationNCT07406282
Recruiting
Phase 1Phase 2

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
AdvanCell Pty Limited100 enrolled3 locationsNCT05720130
Recruiting
Phase 1

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.12 enrolled1 locationNCT07339267
Recruiting
Phase 3

Metastasis-directed Therapy for Oligorecurrent Prostate Cancer

Prostate CancerMetastatic CancerProstate Cancer Metastatic+4 more
Universitaire Ziekenhuizen KU Leuven873 enrolled1 locationNCT05352178
Recruiting

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

Prostate CancerMetastatic TumorHormone Sensitive Prostate Cancer
Santa Chiara Hospital3,000 enrolled3 locationsNCT06473259
Recruiting
Phase 3

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Chemotherapy EffectMetastatic Prostate CancerHormone Sensitive Prostate Cancer
The First Affiliated Hospital with Nanjing Medical University200 enrolled1 locationNCT05983783